SOURCE: SciClone Pharmaceuticals, Inc.

SciClone Pharmaceuticals, Inc.

September 04, 2013 06:00 ET

SciClone to Present at Four Investor Conferences in September 2013

FOSTER CITY, CA--(Marketwired - Sep 4, 2013) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company will present a corporate overview and business update at four upcoming investor conferences in September 2013.

Friedhelm Blobel, PhD, Chief Executive Officer, will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11th at 10:35 am ET at the Grand Hyatt Hotel in New York City, NY.

Dr. Blobel will participate in a panel discussion, titled "BD in China: Why Now is the Time to Partner with Domestics," at the Elsevier Pharmaceutical Strategic Alliances (PSA) conference on Wednesday, September 25th at 9:20 am ET at the Millennium Broadway Hotel in New York City, NY.

Wilson W. Cheung, Chief Financial Officer, will present at the Aegis Capital Corporation 2013 Healthcare Conference on Thursday, September 26th at 11:30 am PT at the Encore at Wynn Hotel in Las Vegas, NV.

Dr. Blobel will present at the BioCentury NewsMakers in the Biotech Industry conference on Friday, September 27th at 11:00 am ET at the Millennium Broadway Hotel in New York City, NY.

To access the live audio webcasts of the Morgan Stanley and BioCentury NewsMakers presentations, please log on through a link located in the Investor Relations section of SciClone's website at, under the Calendar of Events tab. A replay of the webcasts will be available one hour after the conclusion of the live events.

About SciClone

SciClone Pharmaceuticals is a revenue-generating, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone's proprietary lead product, ZADAXIN® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Through its promotion business with pharmaceutical partners, SciClone markets multiple branded products in China which are therapeutically differentiated. The Company has successfully in-licensed products with the potential to become future market leaders and to drive the Company's long-term growth. SciClone is a publicly-held corporation based in Foster City, California, and trades on the NASDAQ Global Select Market under the symbol SCLN. For additional information, please visit

Forward-Looking Statements

This press release contains forward-looking statements regarding expected financial results and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. Please also refer to other risks and uncertainties described in SciClone's filings with the SEC. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.

SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.

Contact Information